Welcome to our dedicated page for Climb Bio news (Ticker: CLYM), a resource for investors and traders seeking the latest updates and insights on Climb Bio stock.
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing monoclonal antibody therapeutics for immune-mediated and B-cell mediated diseases. The CLYM news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow how Climb Bio communicates progress on its pipeline and corporate activities.
News about Climb Bio frequently highlights clinical development updates for its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. Company announcements have covered initiation and enrollment of Phase 2 and Phase 1b/2a trials of budoprutug in primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, as well as a Phase 1 study of a subcutaneous formulation in healthy volunteers. Climb Bio also reports on preclinical and early clinical data, such as long-term follow-up results in pMN and nonhuman primate data for CLYM116 in IgA nephropathy.
Investors and followers can use this news feed to track regulatory milestones, including investigational new drug and clinical trial application clearances, initiation of Phase 1 studies for CLYM116, and updates on trial site activation and dosing progress. Corporate developments, such as leadership appointments, inducement equity grants under the company’s 2025 Inducement Plan, and participation in healthcare and biotechnology investor conferences, are also common topics in Climb Bio’s news flow.
By monitoring CLYM news on Stock Titan, readers gain a centralized view of Climb Bio’s disclosed clinical timelines, data presentations at scientific meetings, and strategic licensing arrangements related to its pipeline. This context can help users understand how the company’s immune-mediated disease programs are advancing through development.
Climb Bio (NASDAQ:CLYM), a clinical-stage biotechnology company, has appointed Susan Altschuller, Ph.D., MBA as Chief Financial Officer. Dr. Altschuller brings over 20 years of strategic and financial leadership experience, notably serving as CFO of Cerevel Therapeutics until its $8.7B AbbVie acquisition and as CFO of ImmunoGen.
As part of her appointment, Dr. Altschuller received an inducement equity award of 600,000 stock options with a ten-year term, vesting over four years. The company is advancing two key programs, budoprutug and CLYM116, with significant clinical data expected in the coming year.
Climb Bio (NASDAQ:CLYM) has announced promising preclinical data for CLYM116, its novel therapeutic candidate for IgA nephropathy (IgAN). The study demonstrated superior performance compared to first-generation anti-APRIL monoclonal antibody sibeprenlimab, showing a 2-3 times longer half-life and deeper IgA reduction of >70%.
The company plans to initiate Phase 1 trials in Q4 2025, with initial data expected by mid-2026. CLYM116's subcutaneous formulation showed 85% bioavailability with favorable tolerability. The market opportunity is significant, estimated at $10-20 billion in the US alone, with approximately 170,000 patients.
Climb Bio (Nasdaq: CLYM) announced a webcast event scheduled for September 29, 2025, at 8:00 a.m. ET to discuss their CLYM116 program and IgA Nephropathy (IgAN) opportunity. The event will feature renowned nephrologist Dr. Craig E. Gordon alongside the company's management team.
CLYM116, a preclinical-stage monoclonal antibody, targets APRIL protein using a unique 'sweeper' mechanism. This approach may offer best-in-class efficacy with reduced dosing frequency. The company plans to file an IND or CTA for CLYM116 in H2 2025.
The webcast will cover IgAN market opportunities, comparative preclinical data, and development strategies. It will be available through Climb Bio's investor relations website.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 16). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM), a clinical-stage biotechnology company focused on immune-mediated disease therapeutics, has announced its participation in four major investor conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (Sept 5), Baird Global Healthcare Conference (Sept 9), Morgan Stanley Annual Global Healthcare Conference (Sept 10), and Stifel Virtual Immunology and Inflammation Forum (Sept 10). Most events will feature fireside chats or presentations along with one-on-one investor meetings.
Live webcasts will be available through Climb Bio's investor relations website, with replays accessible for 30 days after each event.
Climb Bio (Nasdaq: CLYM) reported Q2 2025 financial results and provided significant pipeline updates. The company has advanced its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody.
Key developments include: First patients dosed in both ITP and SLE trials for budoprutug, upcoming initiation of pMN Phase 2 trial, development of a subcutaneous formulation with promising non-clinical data, and advancement of CLYM116 toward clinical development for IgAN. The company appointed Edgar D. Charles, M.D. as Chief Medical Officer.
Financial highlights: $187.4 million in cash and equivalents as of June 30, 2025, with runway through 2027. R&D expenses increased to $6.6 million from $1.0 million year-over-year, while G&A expenses were $4.1 million.
Climb Bio (NASDAQ: CLYM) has granted an inducement equity award to a new employee under its 2025 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The award, granted on May 19, 2025, consists of a non-statutory stock option to purchase 120,000 shares of common stock at an exercise price of $1.27 per share, matching the closing price on Nasdaq Global Market. The option has a ten-year term and vests over four years, with 25% vesting after the first year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.
Climb Bio (NASDAQ: CLYM) reported its Q1 2025 financial results and provided key business updates. The company's lead program budoprutug, an anti-CD19 monoclonal antibody, is advancing with FDA clearances for clinical trials in multiple indications. Clinical studies for ITP and SLE are set to begin in H1 2025, followed by pMN trials in H2 2025.
The company expanded its pipeline with CLYM116, an anti-APRIL monoclonal antibody licensed from Mabworks for IgA nephropathy treatment. Climb Bio strengthened its leadership by appointing two new independent directors and a Chief Business Officer. Financially, the company reported $197.8 million in cash and equivalents, expected to fund operations through 2027. R&D expenses increased to $17.3 million in Q1 2025, including a $9.0 million upfront payment to Mabworks.
Climb Bio (Nasdaq: CLYM) has announced significant changes to its Board of Directors with the appointments of two biotech industry veterans: Kim Cobleigh Drapkin, CPA, and Bo Cumbo. Drapkin, who will serve as Audit Committee Chair, brings over 30 years of financial leadership experience in biotech and pharmaceutical companies, most recently serving as CEO of Graphite Bio.
Cumbo, appointed as Compensation Committee Chair, has 30+ years of experience in the pharmaceutical and biotechnology industries, with a track record of leading 11 successful specialty and rare disease therapy launches. He currently serves as President and CEO of Solid Biosciences.
The appointments come as Climb Bio positions itself for evolution into a late-stage, pre-commercial company focused on immune-mediated diseases. Concurrent with these appointments, Simon Tate will step down from the Board, and Adam Rosenberg will not seek re-election at the 2025 Annual Meeting.